Bukwang Pharmaceutical's Parkinson's Disease Dyskinesia Treatment 'JM-010' Global Clinical Trial Expands to Domestic

[Asia Economy Reporter Chunhee Lee] Bukwang Pharmaceutical announced on the 7th that it will expand the clinical scope of the Phase 2 clinical trial of 'JM-010,' a treatment for Parkinson's disease dyskinesia under development, to include South Korea.

This strategy aims to accelerate the ongoing clinical trials currently being conducted in four European countries?France, Germany, Italy, and Spain?by simultaneously conducting trials domestically. The company submitted an Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safety for this purpose, which was approved on the same day.

This clinical trial is a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of two dosage combinations of JM-010 in patients with moderate to severe Parkinson's disease dyskinesia. The clinical institutions involved are Gil Hospital, Inje University Sanggye Paik Hospital, Yonsei University Severance Hospital, Korea University Ansan Hospital, and Korea University Guro Hospital, totaling five hospitals. The company plans to continuously add institutions, conducting trials at a total of 40 sites across Europe and South Korea.

JM-010 is a new drug candidate developed by Contera Pharma, a Denmark-based biotech venture and a subsidiary of Bukwang Pharmaceutical. It is a drug that can treat dyskinesia, which occurs in nearly 90% of patients who take 'Levodopa,' the primary treatment for Parkinson's disease, over a long period. Currently, Contera Pharma is conducting clinical trials aiming for approval in Europe, while Bukwang Pharmaceutical is conducting trials in the United States.

A representative from Bukwang Pharmaceutical stated, “With the expansion of clinical institutions this time, we will register more patients and accelerate the progress of clinical trials. We will do our utmost to soon provide dyskinesia treatments as essential therapy for Parkinson's disease patients.”